REMINDER: Our focusIR Investor Webinar takes place TONIGHT with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAKR.L Regulatory News (AKR)

  • There is currently no data for AKR

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Appointment of Non-Executive Directors

1 Jul 2013 09:41

RNS Number : 2542I
Akers Biosciences, Inc.
01 July 2013
 



 

1 July 2013

 

 

Akers Biosciences, Inc.

 

("ABI" or the "Company")

 

Appointment of Non-Executive Directors

 

Akers Biosciences, Inc (AIM: AKR), a leading designer and manufacturer of rapid diagnostic screening and testing products, today announces that Gavin Moran and Thomas Knox will be appointed to the board as Non-Executive Directors with effect from 1 July 2013.

 

Mr Moran, aged 43, is an Irish national who has previously worked for Shell International in Shell Chemicals, Marketing, Finance and Shell International Trading. He then held a Trading role as a beneficial shareholder at Trafigura, a leading international commodities trading and logistics company based in Amsterdam and then a Trading role as a beneficial shareholder at Sono International based in London. Mr Moran is indirectly interested through Chubeworkx Guernsey Limited, in which he holds a 31.69 per cent. shareholding, 80 million common shares in the Company, which represents 28.70 per cent of the Company's shares and 24.30 per cent. of the Company's voting rights.

 

Mr Knox, aged 72, is a Philadelphia, Pennsylvania-based businessman who has owned, managed, and ultimately sold multiple profitable companies in the software, banking, and health insurance industries including Disc Systems, Inc., Crusader Bank, Gimco International, Kasser Industries and Fidelity Insurance Group. He also served as Chief Executive Officer for United HealthCare of Pennsylvania and served as Special Deputy Rehabilitator & Chief Executive Officer of Fidelity Mutual Life Insurance Co., Pennsylvania's 5th largest insurer. He currently holds 30 million common shares and 10 million preference shares, which represents 10.76 per cent of the Company's shares and 28.78 per cent. of the Company's voting rights.

 

Raymond F. Akers, Executive Chairman of ABI commented, "It gives me great pleasure to welcome Gavin and Thomas to our Board. They have both invested in the company in the past year and bring with them expertise and experience, which will help move the company forward in the future. My colleagues and I are very much looking forward to our working together."

Further information concerning Mr Moran

Gavin Edwin David Moran's directorships (current and within the previous 5 years) are as follows:

 

Current: None

 

Past: None

 

Further information concerning Mr Knox

 

Thomas James Knox, a Chartered Life Underwriter (CLU) and Chartered Financial Consultant (ChFC), has been involved in Philadelphia politics having held the position of Deputy Mayor for the Office of Management and Productivity. Mr Knox is the Chief Executive Officer of Knox Consulting Group, Knox Family Loan Company and INDECS Corp.

Thomas James Knox's directorships (current and within the previous 5 years) are as follows:

 

Current: Knox Consulting Group

Knox Family Loan Company

INDECS Corp

Historic Philadelphia, Inc.

Newman Wine and Spirit Company

ORB Automotive based in Shenzhen, China

 

Past: None

 

There is no further information required relating to Thomas J. Knox or Gavin E.D. Moran to be disclosed under paragraph (g) of Schedule 2 of the AIM Rules.

 

Enquiries:

Thomas A. Nicolette, President and CEO

Tel. +1 856 848 8698

Antony Legge / James Thomas

Daniel Stewart (Nomad and Broker)

 

 

 

Tel. +44 (0)20 7776 6550

 

 

About Akers Biosciences, Inc.

Akers Biosciences develops, manufactures, and supplies rapid, point of care screening and testing products designed to bring healthcare information both rapidly and directly to the consumer or healthcare provider. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The Company's state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. ABI has aligned with major healthcare companies and high volume medical products distributors to maximize product offerings, and to be a major worldwide competitor in diagnostics. Additional information on the Company and its products can be found at www.akersbiosciences.com

 

End

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAVFLBBXDFXBBK
Date   Source Headline
10th Dec 201210:39 amRNSNotice of AGM
26th Nov 20127:00 amRNSDistribution Partnership Forged in China
22nd Oct 20127:00 amRNSIssue of Equity
8th Oct 201212:00 pmRNSHolding(s) in Company
17th Sep 20127:00 amRNSPrivate Placing
17th Sep 20127:00 amRNSHalf Yearly Report
28th Jun 20127:00 amRNSFinal Results
30th Mar 201210:06 amRNSHolding(s) in Company
27th Feb 20125:01 pmRNSDirectorate Change
6th Jan 20127:00 amRNSTrading Update
6th Dec 20117:00 amRNSLaunch of PIFA PLUSS PF4 Rapid Assay
7th Sep 20117:00 amRNSHalf Yearly Report
24th Aug 20117:00 amRNSClinical Trials Commenced: COPD Rapid Assay
30th Jun 20117:00 amRNSUS$3.2 Million Purchase Order for Revelar
10th May 20115:54 pmRNSResult of AGM
28th Apr 20113:41 pmRNSAnnual Report & Accounts & AGM Notice
27th Apr 20117:00 amRNSUS patent protection grant
18th Apr 20117:00 amRNSAsthma Breath Test - Clinical Trials
11th Apr 20117:02 amRNSFinal Results
11th Apr 20117:00 amRNSSupply Agreement & Technology Acquisition
8th Apr 20117:00 amRNSConclusion of HIT Study
16th Mar 20117:00 amRNSPatent Protection - Rapid Blood Cell Separator
2nd Mar 20114:20 pmRNSHolding(s) in Company
28th Feb 20117:00 amRNSTotal Voting Rights
14th Feb 20113:08 pmRNSTR-1 Notification of Major Interest in Shares
14th Feb 20112:57 pmRNSTR-1 Notification of Major Interest in Shares
10th Feb 20117:00 amRNSIssue of Equity & Director Shareholding
1st Feb 20117:00 amRNSPlacing
14th Jan 20117:00 amRNSBreathScan PRO Receives Regulatory Clearance
5th Jan 20117:00 amRNSTrading Statement
29th Dec 20107:00 amRNSOrder for Tri-Cholesterol Tests - Middle East
16th Nov 20101:14 pmRNSIssue of Equity
30th Sep 20103:57 pmRNSHalf Yearly Report
29th Sep 20107:00 amRNSPIFA Heparin/Platelet Factor-4 - New Data
6th Sep 20107:00 amRNSProduct Distribution Expansion: Middle East/India
12th Aug 20107:00 amRNSFurther Distribution Agreement - PIFA Heparin/PF4
21st Jul 20105:18 pmRNSResult of AGM
21st Jun 20107:00 amRNSFinal Results
18th Jun 20107:00 amRNSBreath Ketone Test - Positive Data
14th Jun 20107:00 amRNSUSA Distribution Agreement
9th Jun 20107:00 amRNSBreathScan Alcohol Detection - Product Extension
26th Mar 20104:52 pmRNSHolding(s) in Company
19th Mar 20101:00 pmRNSChange of Adviser
17th Mar 20107:00 amRNSBreathScan Licensing Agreement - UK & Ireland
16th Mar 20107:00 amRNSClinical Study Data - PIFA Heparin
18th Feb 20109:04 amRNSDirector/PDMR Shareholding
30th Dec 20097:00 amRNSDirectorate Change
17th Dec 20099:23 amRNSHolding(s) in Company
15th Dec 20097:00 amRNSABI Obtains GSA Contract
4th Dec 20097:00 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.